Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Broadwood Partners, the largest shareholder of STAAR Surgical Company, has filed additional proxy materials urging investors to vote against STAAR’s proposed sale to Alcon Inc. Broadwood, which reports owning 27.5% of STAAR’s outstanding common shares, is soliciting votes on its GREEN proxy card for the special shareholder meeting scheduled for October 23, 2025.
In an open letter to STAAR’s board, Broadwood criticizes the sale process and the price agreed with Alcon and calls on the board to hold the vote as scheduled and to respect the outcome. The materials highlight that all three major proxy advisory firms have recommended that shareholders vote against the Alcon transaction and direct shareholders to Broadwood’s campaign website, LetSTAARShine.com, for further information and resources on how to vote.
Broadwood Partners filed additional proxy materials urging STAAR Surgical stockholders to vote “AGAINST” the proposed acquisition by Alcon at the special meeting on October 23, 2025. The filing attaches a press release and website update and notes that all three major proxy advisory firms—ISS, Glass Lewis, and Egan‑Jones—recommend voting against the deal on the GREEN Proxy Card.
Broadwood states that shareholders representing more than 34% of STAAR’s outstanding common shares have publicly opposed the transaction. The materials direct stockholders to review the definitive proxy statement and related documents available on the SEC’s website and Broadwood’s campaign site, LetSTAARShine.com.
STAAR Surgical (STAA) filed an 8-K supplementing its proxy for the proposed merger with Alcon at $28.00 per share. The company disclosed that it will provide additional proxy information ahead of the October 23, 2025 special meeting to adopt the Merger Agreement.
STAAR summarized recent process details and market checks, noting outreach from potential parties and that no competing proposals emerged during the 45-day window shop period ending September 19, 2025. It also highlighted investor positions disclosed since announcement, including Broadwood’s reported 27.3% beneficial ownership and stated opposition, Yunqi’s approximately 5.1% opposition, and support from Soleus at roughly 6%.
The filing adds valuation context from Citi’s analyses: a selected companies EV/2026E revenue range implying about $16.35–$23.80 per share, selected precedent transactions implying about $17.15–$30.80, and a discounted cash flow range of about $17.70–$37.50, each compared with the $28.00 merger consideration.
STAAR Surgical Co. proxy materials criticize the board’s sale process and value choice for a proposed transaction announced one day before
Yunqi Capital files a PX14A6G submission arguing that recent disclosures under the 10-Q show China distributor inventory levels have returned to historical norms and that presenting revenue without this context could mislead shareholders. The filing highlights U.S. expansion spending of "hundreds of millions" that produced modest U.S. revenue growth from about
Yunqi-related investors disclosed a 5.1% stake in STAAR SURGICAL CO (Common Stock). Four reporting persons—Yunqi Path Capital Master Fund, Yunqi Capital Limited, Yunqi Capital Cayman Limited and Christopher Min Fang Wang—each report shared voting and dispositive power over 2,500,061 shares. The group says it acquired Shares beginning in 2023 for investment purposes.
The amendment updates Item 4 to state the Reporting Persons oppose the proposed acquisition of the company by Alcon announced in a
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
